Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

13 Canadian Crypto ETFs (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

Rare Earths Stocks: 9 Biggest Companies in 2024

A State-by-State Guide to Cannabis in Australia (Updated 2024)

Investing in Graphene Companies (Updated 2024)

Mark These Tax-loss Selling Dates on Your Calendar (Updated 2024)

Trending Press Releases

US$30 Million Prepayment Term Sheet and Offtake Agreement Executed with a Global Commodities Trader

Radiopharm achieves Nasdaq listing of ADS

SAGA Metals Reports Channel Sample Assay Results at Double Mer Uranium Project

SAGA Metals Completes OTCQB Listing and Receives DTC Eligibility

Mount Hope Mining: Advancing a Copper, Gold-rich Asset in the Cobar Basin of New South Wales

Significant Milestone Achieved in Development Journey with The Completion of The "first phase" of the Environmental Impact Assessment Procedure for Rajapalot Gold-Cobalt Project

More Press Releases
Trending Companies

Purpose Bitcoin ETF

BTCC:CA

First Helium

HELI:CA

Soma Gold Corp.

SOMA:CA

GTI Energy

GTR:AU
More Companies
Trending Reports

2024 Gold Outlook Report

2024 Uranium Outlook

Silver Price Forecast - What Happened And Where Do We Go From Here?

Rare Earths Outlook Report

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Chemomab Therapeutics Ltd.

NASDAQ:CMMB
Press Releases

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's lead candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Interactive Chart

×